Vertex Pharmaceuticals Incorporated
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor
Phase 3
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: VX-661 Plus Ivacaftor Combination PlaceboDrug: VX-661 Plus Ivacaftor Combination
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 510
- Registration Number
- NCT02347657
Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
Phase 2
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 40
- Registration Number
- NCT02070744
An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 34
- Registration Number
- NCT02015507
Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 33
- Registration Number
- NCT01946412
A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
Phase 3
Completed
- Conditions
- Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
- Interventions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 1164
- Registration Number
- NCT01931839
Phase 1, QT/QTC Interval Study in Healthy Subjects
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 200
- Registration Number
- NCT01910415
A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 28
- Registration Number
- NCT01899105
Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 62
- Registration Number
- NCT01897233
Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects
Phase 1
Completed
- Conditions
- HealthyHepatic Impairment
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 23
- Registration Number
- NCT01888393
Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Drug Interactions
- Interventions
- First Posted Date
- 2013-06-25
- Last Posted Date
- 2013-08-14
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 28
- Registration Number
- NCT01886209
- Locations
- πΊπΈ
Vertex Investigational Site, Lenexa, Kansas, United States